1.New insights into the role of heme oxygenase-1 in acute kidney injury
Kidney Research and Clinical Practice 2020;39(4):387-401
Acute kidney injury (AKI) is attended by injury-related biomarkers appearing in the urine and serum, decreased urine output, and impaired glomerular filtration rate. AKI causes increased morbidity and mortality and can progress to chronic kidney disease and end-stage kidney failure. AKI is without specific therapies and is managed by supported care. Heme oxygenase-1 (HO-1) is a cytoprotective, inducible enzyme that degrades toxic free heme released from destabilized heme proteins and, during this process, releases beneficial by-products such as carbon monoxide and biliverdin/bilirubin and promotes ferritin synthesis. HO-1 induction protects against assorted renal insults as demonstrated by in vitro and preclinical models. This review summarizes the advances in understanding of the protection conferred by HO-1 in AKI, how HO-1 can be induced including via its transcription factor Nrf2, and HO-1 induction as a therapeutic strategy.
2.New insights into the role of heme oxygenase-1 in acute kidney injury
Kidney Research and Clinical Practice 2020;39(4):387-401
Acute kidney injury (AKI) is attended by injury-related biomarkers appearing in the urine and serum, decreased urine output, and impaired glomerular filtration rate. AKI causes increased morbidity and mortality and can progress to chronic kidney disease and end-stage kidney failure. AKI is without specific therapies and is managed by supported care. Heme oxygenase-1 (HO-1) is a cytoprotective, inducible enzyme that degrades toxic free heme released from destabilized heme proteins and, during this process, releases beneficial by-products such as carbon monoxide and biliverdin/bilirubin and promotes ferritin synthesis. HO-1 induction protects against assorted renal insults as demonstrated by in vitro and preclinical models. This review summarizes the advances in understanding of the protection conferred by HO-1 in AKI, how HO-1 can be induced including via its transcription factor Nrf2, and HO-1 induction as a therapeutic strategy.
3.Letter to the Editor: Individual Researcher and Author Metrics: a Viewpoint from India.
Durga Prasanna MISRA ; Anupam WAKHLU ; Vikas AGARWAL
Journal of Korean Medical Science 2018;33(28):e202-
No abstract available.
India*
4.Letter to the Editor: Appropriate Statistical Analysis and Research Reporting.
Durga Prasanna MISRA ; Anupam WAKHLU ; Vikas AGARWAL ; Aman SHARMA ; Vir Singh NEGI
Journal of Korean Medical Science 2017;32(8):1379-1380
No abstract available.
Research Report*
5.Plagiarism: a Viewpoint from India.
Durga Prasanna MISRA ; Vinod RAVINDRAN ; Anupam WAKHLU ; Aman SHARMA ; Vikas AGARWAL ; Vir Singh NEGI
Journal of Korean Medical Science 2017;32(11):1734-1735
No abstract available.
India*
;
Plagiarism*
6.Letter to the Editor: An Indian Perspective on Universal Open Access Publishing: Think of the Fire before Venturing Out of the Frying Pan!
Durga Prasanna MISRA ; Vinod RAVINDRAN ; Aman SHARMA ; Anupam WAKHLU ; Sakir AHMED ; Vir Singh NEGI ; Vikas AGARWAL
Journal of Korean Medical Science 2020;35(8):85-
No abstract available.
Fires
;
Open Access Publishing
7.Letter to the Editor: An Indian Perspective on Universal Open Access Publishing: Think of the Fire before Venturing Out of the Frying Pan!
Durga Prasanna MISRA ; Vinod RAVINDRAN ; Aman SHARMA ; Anupam WAKHLU ; Sakir AHMED ; Vir Singh NEGI ; Vikas AGARWAL
Journal of Korean Medical Science 2020;35(8):e85-
Result Analysis
Print
Save
E-mail